Jinru Shia
Memorial Sloan Kettering Cancer Center
405 Papers
1.4K Citations
Jinru Shia is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Colorectal cancer. The author has an hindex of 81, co-authored 332 publications. Previous affiliations of Jinru Shia include Kettering University & Cornell University.
Chat about Author
Papers
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.
Michael J. Morris,Jean T. Santamauro,Jinru Shia,Lawrence H. Schwartz,Nicholas Vander Els,Kevin Kelly,Howard I. Scher +6 more
TL;DR: The clinical, pathologic, and radiographic data support drug toxicity as the likely etiology of androgen-independent disease and recommend that patients receiving weekly docetaxel, with or without estramustine, have frequent treatment breaks and be evaluated with computed tomography of the chest every 8 weeks.
13
Molecular Screening for Lynch Syndrome in Young Patients with Colorectal Adenomas
TL;DR: Routine screening of polyps in patients aged < 50 years old is not an effective tool for identifying Lynch syndrome carriers and the results indicate that routine polyp staining for MMR did not effectively identify LS carriers.
13
Lymph node yield after colectomy for cancer: is absence of mismatch repair a factor?
Tushar Samdani,Molly Schultheis,Zsofia K. Stadler,Jinru Shia,Tiffany T. Fancher,Justine Misholy,Martin R. Weiser,Garrett M. Nash +7 more
TL;DR: Pat age, length of bowel resected, lymph node ratio, perineural invasion, tumor size, and tumor location were significant predictors of lymph nodes yield, however, when controlling for surgical and pathologic factors, mismatch repair protein expression did not predict lymph node yield.
Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis.
TL;DR: Investigation revealed a collision-type primary tumor of the large bowel, containing adenocarcinoma and neuroendocrine elements, and platinum-based chemotherapy resulted in a divergent pathologic response as assessed after colectomy.
13
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
James J. Harding,Robin Kate Kelley,Benjamin R. Tan,Marinela Capanu,Gian Kinh Do,Jinru Shia,Joanne F. Chou,Christine S. Ferrer,Chayma Boussayoud,Kerri E. Muenkel,Hooman Yarmohammadi,Imane El Dika,Danny N. Khalil,Carmen Ruiz,Mariam Rodriguez-Lee,Peter Kuhn,John Wilton,Renuka Iyer,Ghassan K. Abou-Alfa +18 more
TL;DR: Enzalutamide is ineffective in HCC; further development is not supported by this study.
13